Emerging Concepts in Fibroblast Biology and Progressive Pulmonary Fibrosis

Abstract

Pulmonary fibrosis is characterized by scarring and thickening of the lung parenchyma due to excessive deposition of collagen and other extracellular matrix (ECM) proteins. This leads to disruption of gas exchange areas and ultimately respiratory failure, a pathology shared across multiple interstitial lung diseases (ILDs). Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive ILD characterized by exertional dyspnea, dry cough, and restrictive lung defects. Clinical progression is marked by worsening lung function, declining exercise tolerance, and hypoxemia. High-resolution computed tomography in IPF typically shows reticular opacities and honeycombing, predominantly distributed in the subpleural regions and lower lobes of the lungs. The disease course is variable, with episodes of acute exacerbation associated with high mortality. Myofibroblasts and fibroblasts are central drivers of fibrogenesis through uncontrolled proliferation, migration, survival, senescence, myofibroblast differentiation, and ECM production. Myofibroblasts represent a heterogeneous population in both origin and function, arising from diverse precursor cells, including lung resident fibroblasts, endothelial cells, and mesothelial cells, and are shaped by tissue-specific niches. Persistent activation of (myo)fibroblasts is sustained by a complex network of profibrotic growth factors and their downstream transcriptional regulators. In this review, we comprehensively examine the cellular origins and molecular pathways underlying fibroblast activation, with an emphasis on mechanistic insights that may inform the development of targeted antifibrotic therapies to attenuate disease progression and improve patient outcomes.

Keywords

idiopathic pulmonary fibrosis - fibroblast - collagen - lung - extracellular matrix

Publication History

Accepted Manuscript online:
24 July 2025

Article published online:
12 August 2025

• References

• 1 Borie R, Tabèze L, Thabut G. et al. Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. Eur Respir J 2016; 48 (06) 1721-1731
• 2 Bilgili H, Białas AJ, Górski P, Piotrowski WJ. Telomere abnormalities in the pathobiology of idiopathic pulmonary fibrosis. J Clin Med 2019; 8 (08) 1232
• 3 Peljto AL, Selman M, Kim DS. et al. The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries. Chest 2015; 147 (02) 460-464
• 4 Gooptu B. Surfactant protein C mutations and familial pulmonary fibrosis: stuck in a loop on the scenic route. Eur Respir J 2022; 59 (01) 2102147
• 5 Li F, Deng J, Song Y. et al. Pulmonary fibrosis in patients with COVID-19: A retrospective study. Front Cell Infect Microbiol 2022; 12: 1013526
• 6 Yoshida T, Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev 2007; 87 (03) 1047-1082
• 7 Huang WJ, Tang XX. Virus infection induced pulmonary fibrosis. J Transl Med 2021; 19 (01) 496
• 8 Lazar M, Barbu EC, Chitu CE. et al. Interstitial lung fibrosis following COVID-19 pneumonia. Diagnostics (Basel) 2022; 12 (08) 2028
• 9 Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med 2020; 201 (06) 650-660
• 10 Liaskos C, Rentouli S, Simopoulou T. et al. Anti-C1q autoantibodies are frequently detected in patients with systemic sclerosis associated with pulmonary fibrosis. Br J Dermatol 2019; 181 (01) 138-146
• 11 Kadota T, Fujita Y, Araya J, Ochiya T, Kuwano K. Extracellular vesicle-mediated cellular crosstalk in lung repair, remodelling and regeneration. Eur Respir Rev 2022; 31 (163) 210106
• 12 Worrell JC, MacLeod MKL. Stromal-immune cell crosstalk fundamentally alters the lung microenvironment following tissue insult. Immunology 2021; 163 (03) 239-249
• 13 Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011; 208 (07) 1339-1350
• 14 Sontake V, Kasam RK, Sinner D. et al. Wilms' tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease. JCI Insight 2018; 3 (16) e121252
• 15 Gaikwad AV, Lu W, Dey S. et al. Vascular remodelling in idiopathic pulmonary fibrosis patients and its detrimental effect on lung physiology: potential role of endothelial-to-mesenchymal transition. ERJ Open Res 2022; 8 (01) 00571-02021
• 16 Rieder F, Kessler SP, West GA. et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol 2011; 179 (05) 2660-2673
• 17 Koopmans T, Rinkevich Y. Mesothelial to mesenchyme transition as a major developmental and pathological player in trunk organs and their cavities. Commun Biol 2018; 1: 170
• 18 Liu X, Dai K, Zhang X. et al. Multiple fibroblast subtypes contribute to matrix deposition in pulmonary fibrosis. Am J Respir Cell Mol Biol 2023; 69 (01) 45-56
• 19 Valenzi E, Bulik M, Tabib T. et al. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease. Ann Rheum Dis 2019; 78 (10) 1379-1387
• 20 Goss AM, Tian Y, Cheng L. et al. Wnt2 signaling is necessary and sufficient to activate the airway smooth muscle program in the lung by regulating myocardin/Mrtf-B and Fgf10 expression. Dev Biol 2011; 356 (02) 541-552
• 21 Peng T, Tian Y, Boogerd CJ. et al. Coordination of heart and lung co-development by a multipotent cardiopulmonary progenitor. Nature 2013; 500 (7464) 589-592
• 22 Zhang W, Menke DB, Jiang M. et al. Spatial-temporal targeting of lung-specific mesenchyme by a Tbx4 enhancer. BMC Biol 2013; 11: 111
• 23 Kumar ME, Bogard PE, Espinoza FH, Menke DB, Kingsley DM, Krasnow MA. Mesenchymal cells. Defining a mesenchymal progenitor niche at single-cell resolution. Science 2014; 346 (6211) 1258810
• 24 Uchida K, Yoshida Y, Kodo K, Yamagishi H. : Roles of Tbx4 in the Lung Mesenchyme for Airway and Vascular Development. 2020 :79–81.
• 25 Xie T, Liang J, Liu N. et al. Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis. J Clin Invest 2016; 126 (08) 3063-3079
• 26 German K, Deutsch GH, Freed AS, Dipple KM, Chabra S, Bennett JT. Identification of a deletion containing TBX4 in a neonate with acinar dysplasia by rapid exome sequencing. Am J Med Genet A 2019; 179 (05) 842-845
• 27 Arora R, Metzger RJ, Papaioannou VE. Multiple roles and interactions of Tbx4 and Tbx5 in development of the respiratory system. PLoS Genet 2012; 8 (08) e1002866
• 28 Bongers EM, Duijf PH, van Beersum SE. et al. Mutations in the human TBX4 gene cause small patella syndrome. Am J Hum Genet 2004; 74 (06) 1239-1248
• 29 Luo Y, Xu W, Chen H. et al. A novel profibrotic mechanism mediated by TGFβ-stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells. J Pathol 2015; 236 (03) 384-394
• 30 Ntokou A, Klein F, Dontireddy D. et al. Characterization of the platelet-derived growth factor receptor-α-positive cell lineage during murine late lung development. Am J Physiol Lung Cell Mol Physiol 2015; 309 (09) L942-L958
• 31 Green J, Endale M, Auer H, Perl AKT. Diversity of interstitial lung fibroblasts is regulated by platelet-derived growth factor receptor α kinase activity. Am J Respir Cell Mol Biol 2016; 54 (04) 532-545
• 32 Jones DL, Morley MP, Li X. et al. An injury-induced tissue niche shaped by mesenchymal plasticity coordinates the regenerative and disease response in the lung. bioRxiv 2024
• 33 Fang Y, Chung SSW, Xu L. et al. RUNX2 promotes fibrosis via an alveolar-to-pathological fibroblast transition. Nature 2025
• 34 Tsukui T, Wolters PJ, Sheppard D. Alveolar fibroblast lineage orchestrates lung inflammation and fibrosis. Nature 2024; 631 (8021) 627-634
• 35 Lingampally A, Truchi M, Mauduit O. et al. Evidence for a lipofibroblast-to-Cthrc1⁺ myofibroblast reversible switch during the development and resolution of lung fibrosis in young mice. Eur Respir J 2025; 65 (02) 65
• 36 Park J, Ivey MJ, Deana Y. et al. The Tcf21 lineage constitutes the lung lipofibroblast population. Am J Physiol Lung Cell Mol Physiol 2019; 316 (05) L872-L885
• 37 Tsukui T, Sheppard D. : Tracing the Origin of Pathologic Pulmonary Fibroblasts. 2022
• 38 Tsukui T, Sun K-H, Wetter JB. et al. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat Commun 2020; 11 (01) 1920
• 39 Ruiz-Villalba A, Romero JP, Hernández SC. et al. Single-cell RNA sequencing analysis reveals a crucial role for CTHRC1 (collagen triple helix repeat containing 1) cardiac fibroblasts after myocardial infarction. Circulation 2020; 142 (19) 1831-1847
• 40 Hironaka T, Takizawa N, Yamauchi Y, Horii Y, Nakaya M. The well-developed actin cytoskeleton and Cthrc1 expression by actin-binding protein drebrin in myofibroblasts promote cardiac and hepatic fibrosis. J Biol Chem 2023; 299 (03) 102934
• 41 Li J, Wang Y, Ma M. et al. Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling. EBioMedicine 2019; 40: 43-55
• 42 Li H, Liu W, Zhang X, Wang Y. Cancer-associated fibroblast-secreted collagen triple helix repeat containing-1 promotes breast cancer cell migration, invasiveness and epithelial-mesenchymal transition by activating the Wnt/β-catenin pathway. Oncol Lett 2021; 22 (06) 814
• 43 Binks AP, Beyer M, Miller R, LeClair RJ. Cthrc1 lowers pulmonary collagen associated with bleomycin-induced fibrosis and protects lung function. Physiol Rep 2017; 5 (05) e13115
• 44 Moeller A, Gilpin SE, Ask K. et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179 (07) 588-594
• 45 Heukels P, van Hulst JAC, van Nimwegen M. et al. Fibrocytes are increased in lung and peripheral blood of patients with idiopathic pulmonary fibrosis. Respir Res 2018; 19 (01) 90
• 46 Borie R, Quesnel C, Phin S. et al. Detection of alveolar fibrocytes in idiopathic pulmonary fibrosis and systemic sclerosis. PLoS One 2013; 8 (01) e53736
• 47 Madala SK, Edukulla R, Schmidt S, Davidson C, Ikegami M, Hardie WD. Bone marrow-derived stromal cells are invasive and hyperproliferative and alter transforming growth factor-α-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2014; 50 (04) 777-786
• 48 Roife D, Fleming JB, Gomer RH. Fibrocytes in the tumor microenvironment. Adv Exp Med Biol 2020; 1224: 79-85
• 49 Kleaveland KR, Moore BB, Kim KK. Paracrine functions of fibrocytes to promote lung fibrosis. Expert Rev Respir Med 2014; 8 (02) 163-172
• 50 Pilling D, Vakil V, Cox N, Gomer RH. TNF-α-stimulated fibroblasts secrete lumican to promote fibrocyte differentiation. Proc Natl Acad Sci U S A 2015; 112 (38) 11929-11934
• 51 Sontake V, Shanmukhappa SK, DiPasquale BA. et al. Fibrocytes regulate Wilms tumor 1-positive cell accumulation in severe fibrotic lung disease. J Immunol 2015; 195 (08) 3978-3991
• 52 Rock JR, Barkauskas CE, Cronce MJ. et al. Multiple Stromal Populations Contribute to Pulmonary Fibrosis Without Evidence for Epithelial to Mesenchymal Transition. Proceedings of the National Academy of Sciences 2011 , 108
• 53 Hung CF, Wilson CL, Chow YH. et al. Effect of lung pericyte-like cell ablation on the bleomycin model of injury and repair. Am J Physiol Lung Cell Mol Physiol 2022; 322 (04) L607-L616
• 54 Hung C, Linn G, Chow YH. et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 2013; 188 (07) 820-830
• 55 Mubarak KK, Montes-Worboys A, Regev D. et al. Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. Eur Respir J 2012; 39 (01) 133-140
• 56 Bellaye PS, Burgy O, Colas J. et al. Antifibrotic role of αB-crystallin inhibition in pleural and subpleural fibrosis. Am J Respir Cell Mol Biol 2015; 52 (02) 244-252
• 57 Yamamoto Y, Baldwin HS, Prince LS. Endothelial differentiation by multipotent fetal mouse lung mesenchymal cells. Stem Cells Dev 2012; 21 (09) 1455-1465
• 58 Gaikwad AV, Lu W, Dey S. et al. Endothelial-to-mesenchymal transition: a precursor to pulmonary arterial remodelling in patients with idiopathic pulmonary fibrosis. ERJ Open Res 2023; 9 (02) 00487-02022
• 59 Nicolosi PA, Tombetti E, Giovenzana A. et al. Macrophages guard endothelial lineage by hindering endothelial-to-mesenchymal transition: implications for the pathogenesis of systemic sclerosis. J Immunol 2019; 203 (01) 247-258
• 60 Raslan AA, Pham TX, Lee J. et al. Lung injury-induced activated endothelial cell states persist in aging-associated progressive fibrosis. Nat Commun 2024; 15 (01) 5449
• 61 Yoshimatsu Y, Watabe T. Roles of TGF-β signals in endothelial-mesenchymal transition during cardiac fibrosis. Int J Inflamm 2011; 2011: 724080
• 62 Kim KK, Kugler MC, Wolters PJ. et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A 2006; 103 (35) 13180-13185
• 63 Hoyles RK, Derrett-Smith EC, Khan K. et al. An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor. Am J Respir Crit Care Med 2011; 183 (02) 249-261
• 64 Lee T-H, Yeh C-F, Lee Y-T. et al. Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFβ signaling through TGFBR1 stabilization. Nat Commun 2020; 11 (01) 4254
• 65 Epstein Shochet G, Brook E, Bardenstein-Wald B, Shitrit D. TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling. Respir Res 2020; 21 (01) 56
• 66 Tatler AL, Jenkins G. TGF-β activation and lung fibrosis. Proc Am Thorac Soc 2012; 9 (03) 130-136
• 67 Khalil N, Xu YD, O'Connor R, Duronio V. Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-β1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J Biol Chem 2005; 280 (52) 43000-43009
• 68 Zhao J, Shi W, Wang Y-L. et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002; 282 (03) L585-L593
• 69 Sheppard D. Epithelial-mesenchymal interactions in fibrosis and repair. Transforming growth factor-β activation by epithelial cells and fibroblasts. Ann Am Thorac Soc 2015; 12 (Suppl. 01) S21-S23
• 70 Korfhagen TR, Le Cras TD, Davidson CR. et al. Rapamycin prevents transforming growth factor-α-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2009; 41 (05) 562-572
• 71 Chung EJ, Hudak K, Horton JA. et al. Transforming growth factor alpha is a critical mediator of radiation lung injury. Radiat Res 2014; 182 (03) 350-362
• 72 Hardie WD, Hagood JS, Dave V. et al. Signaling pathways in the epithelial origins of pulmonary fibrosis. Cell Cycle 2010; 9 (14) 2769-2776
• 73 Hardie WD, Davidson C, Ikegami M. et al. EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-α-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294 (06) L1217-L1225
• 74 Hostettler KE, Zhong J, Papakonstantinou E. et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res 2014; 15 (01) 157
• 75 Kishi M, Aono Y, Sato S. et al. Blockade of platelet-derived growth factor receptor-β, not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice. PLoS One 2018; 13 (12) e0209786
• 76 Abdollahi A, Li M, Ping G. et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005; 201 (06) 925-935
• 77 Pan LH, Yamauchi K, Uzuki M. et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J 2001; 17 (06) 1220-1227
• 78 MacKenzie B, Korfei M, Henneke I. et al. Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis. Respir Res 2015; 16 (01) 83
• 79 Joannes A, Brayer S, Besnard V. et al. FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro. Am J Physiol Lung Cell Mol Physiol 2016; 310 (07) L615-L629
• 80 Lam AP, Flozak AS, Russell S. et al. Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol 2011; 45 (05) 915-922
• 81 Trinh-Minh T, Chen C-W, Tran Manh C. et al. Noncanonical WNT5A controls the activation of latent TGF-β to drive fibroblast activation and tissue fibrosis. J Clin Invest 2024; 134 (10) 134
• 82 Newman DR, Sills WS, Hanrahan K. et al. Expression of WNT5A in idiopathic pulmonary fibrosis and its control by TGF-β and WNT7B in human lung fibroblasts. J Histochem Cytochem 2016; 64 (02) 99-111
• 83 Cao H, Chen X, Hou J. et al. The Shh/Gli signaling cascade regulates myofibroblastic activation of lung-resident mesenchymal stem cells via the modulation of Wnt10a expression during pulmonary fibrogenesis. Lab Invest 2020; 100 (03) 363-377
• 84 Aumiller V, Balsara N, Wilhelm J, Günther A, Königshoff M. WNT/β-catenin signaling induces IL-1β expression by alveolar epithelial cells in pulmonary fibrosis. Am J Respir Cell Mol Biol 2013; 49 (01) 96-104
• 85 Baarsma HA, Königshoff M. ‘WNT-er is coming’: WNT signalling in chronic lung diseases. Thorax 2017; 72 (08) 746-759
• 86 Liu T, Gonzalez De Los Santos F, Hirsch M, Wu Z, Phan SH. Noncanonical Wnt signaling promotes myofibroblast differentiation in pulmonary fibrosis. Am J Respir Cell Mol Biol 2021; 65 (05) 489-499
• 87 Yang F, Hou ZF, Zhu HY. et al. Catalpol protects against pulmonary fibrosis through inhibiting TGF-β1/Smad3 and Wnt/β-catenin signaling pathways. Front Pharmacol 2021; 11: 594139
• 88 Henderson Jr WR, Chi EY, Ye X. et al. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A 2010; 107 (32) 14309-14314
• 89 Ding H, Zhou D, Hao S. et al. Sonic hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fibrosis. J Am Soc Nephrol 2012; 23 (05) 801-813
• 90 Ho EK, Stearns T. Hedgehog signaling and the primary cilium: implications for spatial and temporal constraints on signaling. Development 2021; 148 (09) 148
• 91 Gajjala PR, Singh P, Odayar V, Ediga HH, McCormack FX, Madala SK. Wilms tumor 1-driven fibroblast activation and subpleural thickening in idiopathic pulmonary fibrosis. Int J Mol Sci 2023; 24 (03) 2850
• 92 Gajjala PR, Kasam RK, Soundararajan D. et al. Dysregulated overexpression of Sox9 induces fibroblast activation in pulmonary fibrosis. JCI Insight 2021; 6 (20) 6